Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 6 for:    IMO-2125

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03052205
Recruitment Status : Active, not recruiting
First Posted : February 14, 2017
Last Update Posted : August 8, 2019
Sponsor:
Information provided by (Responsible Party):
Idera Pharmaceuticals, Inc.

Brief Summary:
This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.

Condition or disease Intervention/treatment Phase
Refractory Solid Tumors Melanoma Drug: IMO-2125 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Actual Study Start Date : June 9, 2017
Actual Primary Completion Date : July 31, 2019
Estimated Study Completion Date : April 2020


Arm Intervention/treatment
Experimental: IMO-2125 at escalating dose levels
IMO-2125 at escalating dose levels by intratumoral injection
Drug: IMO-2125
IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.




Primary Outcome Measures :
  1. Dose Evaluation Cohorts, non-Melanoma Dose Evaluation Cohorts: Number of patients with treatment-related adverse events as assessed by CTCAE to determine the recommended Phase 2 dose (RP2D). [ Time Frame: 51 weeks of treatment ]
  2. Dose Evaluation Cohorts, non-Melanoma Dose Evaluation Cohorts: Objective response rate [ Time Frame: Assessed every 6 weeks for duration of study participation, which is estimated to be 51 weeks ]
  3. Melanoma Expansion Cohort: Objective response rate [ Time Frame: Assessed every 9 weeks for duration of study participation, which is estimated to be 51 weeks ]
  4. Melanoma Expansion Cohort: Number of patients with treatment-related adverse events as assessed by CTCAE [ Time Frame: 51 weeks of treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have histologically or cytologically confirmed diagnosis of cancer not amenable to curative therapy.
  2. Patients who have a diagnosis for which a PD-(L)-1 inhibitor has been approved must have previously received treatment with one of these therapies.

    a. Melanoma Dose Expansion: Patients must have histologically confirmed metastatic melanoma (ocular melanoma not included) which has progressed on or after treatment with a PD-(L)1 inhibitor.

  3. a) Dose Evaluation Portion: Patients should have at least one lesion accessible for intratumoral injection and biopsy.

    b) Melanoma Expansion Cohort: Patients must have at least one target lesion by Response Evaluation Criteria for Solid Tumors (RECIST v1.1), with at least one lesion accessible for intratumoral injection. Tumor biopsies are not required in the expansion cohort.

  4. Patients must be 18 years of age or older.
  5. Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.
  6. Patients must meet the following laboratory criteria:

    1. Absolute neutrophil count ANC ≥1.5 x 109/L (≥1500/mm3)
    2. Platelet count ≥75 x 109/L (≥75,000/mm3)
    3. Hemoglobin ≥8.0 g/dL (≥4.96 mmol/L)
    4. Serum creatinine ≤1.5 x ULN or calculated 24-hour creatinine clearance ≥60 mL/minute
    5. Aspartate aminotransferase (AST) ≤2.5 x ULN; ALT ≤2.5 x ULN or AST/ALT <5 x ULN if liver involvement
    6. Total bilirubin ≤1.5 x ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin <3 mg/dL (51.3 μmol/L)
  7. Women of childbearing potential and men must agree to use effective contraceptive methods from Screening throughout the study treatment period and until at least 4 weeks after the last dose of study drug.
  8. Patients must be willing and able to provide signed informed consent and comply with the study protocol.

Exclusion Criteria:

  1. Patients who have received prior therapy with a TLR agonist Patients who have received experimental vaccines or immune therapies other than PD-(L)1 or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (e.g., Imlygic®) should be discussed with the Medical Monitor to confirm eligibility.

    Note: (prior treatment with a topical TLR agonist (e.g. imiquimod) is permitted).

  2. Patients who have received treatment with IFN-α within the previous 6 months prior to enrollment.
  3. Patients with known hypersensitivity to any oligodeoxynucleotide that cannot be adequately managed with appropriate prophylaxis; e.g. steroids.
  4. Patients with active autoimmune disease requiring disease-modifying therapy.
  5. Patients requiring concurrent systemic steroid therapy higher than physiologic dosage (>10mg/day of prednisone or equivalent).
  6. Patients with another primary malignancy that has not been in remission for at least 3 years, unless approved by the Idera Medical Monitor. The following are exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer with non-detectable prostate-specific antigen, cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou (Pap) smear, and thyroid cancer (except anaplastic).
  7. Patients with active infections requiring systemic treatment.
  8. Patients who are known to be hepatitis B surface antigen positive.
  9. Patients with a known diagnosis of human immunodeficiency virus (HIV) infection.
  10. Women who are pregnant or breastfeeding.
  11. Patients with known central nervous system, meningeal, or epidural disease. Patients with stable brain metastases following definitive local treatment are eligible if steroid requirement is <10 mg/day of prednisone (or equivalent).
  12. Patients with impaired cardiac function or clinically significant cardiac disease:

    1. New York Heart Association Class III or IV cardiac disease, including preexisting clinically significant ventricular arrhythmia, congestive heart failure, or cardiomyopathy
    2. Unstable angina pectoris ≤6 months prior to study participation
    3. Acute myocardial infarction ≤6 months prior to study participation
    4. Other clinically significant heart disease (i.e., Grade ≥3 hypertension, history of labile hypertension, or poor compliance with an anti-hypertensive regimen)
  13. Have not recovered (to baseline or Grade ≤1) from toxicity associated with prior treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03052205


Locations
Layout table for location information
United States, Arizona
Scottsdale Healthcare Hospitals DBA Honor Health
Scottsdale, Arizona, United States, 85258
The University of Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, California
University of California San Francisco (UCSF)
San Francisco, California, United States, 94143
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
United States, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
St. Luke's Hospital
Easton, Pennsylvania, United States, 18045
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Israel
Rambam Medical Center
Haifa, Israel, 3109601
Hadassah Medical Center
Jerusalem, Israel, 9112001
Rabin Medical Center Beilinson Campus
Petah tikva, Israel, 49100
The Ella Lemelbaum Institute for Immuno-Oncology
Ramat Gan, Israel, 5265601
Sponsors and Collaborators
Idera Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Idera Medical Director Idera Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Idera Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03052205     History of Changes
Other Study ID Numbers: 2125-RST-101
First Posted: February 14, 2017    Key Record Dates
Last Update Posted: August 8, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Idera Pharmaceuticals, Inc.:
ILLUMINATE-101
melanoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas